Dr. Reddy's Laboratories Limited — Others, 09-05-2025: Change in Management

Dr. Reddy’s Laboratories has announced a board meeting on finalizing the financial results for the quarter and half-year. Consolidated revenues grew 20% YoY to ₹8,506 Cr, led by Global Generics, Pharmaceutical Services, and the Nicotine Replacement Therapy acquisition. Profit before tax rose 25% YoY to ₹2,005 Cr, with net profit up 22% YoY at ₹1,594 Cr. The final dividend is ₹8 per share. The company launched multiple new products across key markets and continues steady R&D investment (8.5% of revenues). Mr. G.V. Prasad was re-appointed as Co-Chairman and MD for five years, and a new secretarial auditor was appointed. Investigations on past U.S. anti-corruption issues are ongoing but unlikely to impact operations. Cash position remains strong at ₹1,465 Cr with a net debt-equity ratio of (0.07).